Freya Biosciences, a Copenhagen, Denmark- and Boston, Massachusetts-based biotech company specializing in women’s health, raised $38m Series A financing.
The round was led by Sofinnova Partners and OMX Ventures, with participation from The Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family Office, CE-Ventures, Corundum Systems Biology, and Indaco Venture Partners.
The company intends to use the funds to advance the clinical development of its lead drug candidate, an investigational vaginal microbial immunotherapeutic, for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART) and its multi-omics data science platform, which includes deep microbiome sequencing and vast multiplexed immune biomarker profiling in human clinical samples.
Led by CEO Colleen Acosta, Freya Biosciences is a clinical-stage biotech company with headquarters in Copenhagen, Denmark and Boston, Massachusetts dedicated to reimagining women’s health and redefine fertility for those previously deprived of options. With a focus on microbial immunotherapies, it addresses immune drivers underlying a range of reproductive health conditions to create a future where everyone is empowered with optimal reproductive health.
FinSMEs
12/12/2023